Developer docs
API playgroundTry for free, no card

Search company profiles

Inceptor Bio

Full company profile

uuid0000nu1

Namestring
Inceptor Bio
Legal namestring
Inceptor Bio, LLC
Websiteurl
inceptor.bio
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Inceptor Bio is a clinical-stage biotechnology company founded in May 2020 and headquartered in Morrisville, North Carolina (Research Triangle Park). The company develops engineered cell therapies — spanning CAR-T, CAR-M (macrophage), and CAR-NK (natural killer) modalities — for solid tumors. Its lead program, IB-T101, is an autologous CAR-T therapy directed at CD70-expressing cancers, with an initial indication in clear cell renal cell carcinoma (ccRCC); the first patient was dosed in February 2025 in a Phase 1 trial. The lead indication addresses a market of more than 300,000 new ccRCC cases annually worldwide.

The company's core technical differentiator is the OUTLAST™ platform, which metabolically reprograms T cells to persist and function within the hostile tumor microenvironment — a documented failure mode for conventional CAR-T therapies in solid tumors. Inceptor operates an in-house GMP manufacturing facility in Gainesville, Florida, acquired in 2022, providing process control and production independence for clinical supply. The pipeline also includes exploratory CAR-M and CAR-NK programs targeting the same CD70 antigen, and the company has established an in-house manufacturing footprint plus a series of preclinical data packages supporting the IB-T101 mechanism.

Inceptor is pre-revenue, with no approved or commercial products. Its business model is two-pronged: (1) internal development and eventual commercialization of proprietary cell therapies, either independently or with a future commercial partner, and (2) near-term licensing revenue through territorial partnerships — exemplified by its December 2024 deal with GRIT Bio granting China rights to IB-T101, which provides milestone and royalty upside. The company has raised approximately $84 million across multiple funding rounds since inception, with Kineticos Life Sciences as a consistent financial backer, and is led by CEO Matthias Schroff (formerly of Exicure) and Founder/Executive Chair Shailesh Maingi.

Short descriptiontext

Inceptor Bio is a clinical-stage biotech developing CAR-T, CAR-M, and CAR-NK cell therapies for solid tumors, with lead program IB-T101 targeting CD70 in clear cell renal cell carcinoma. Pre-revenue, it earns milestone and royalty revenue via territorial licensing partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy development, CAR-T therapy, oncology biotechnology, solid tumor treatment, immunotherapy platform
Industry3 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Therapy Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biotechnology company developing cell therapies for cancer treatment. Revenue expected from future therapeutic product sales upon regulatory approval.

inceptor.bio
2Partnership Milestones and Royalties
TypeLicensing Royalties
Description

Receives milestone payments and royalties from GRIT Bio partnership upon IB-T101 achieving certain response criteria and regulatory milestones in China.

inceptor.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1OUTLAST™ Platform
Description

Proprietary platform that metabolically reprograms T cells to thrive in the hostile tumor microenvironment by conditioning for the fittest, most persistent cells through controlled TME-like stress.

inceptor.bio
Core offering1 text field

Inceptor Bio develops next-generation autologous cell therapies for solid tumors, with lead candidate IB-T101, a CD70-targeted CAR-T therapy for clear cell Renal Cell Carcinoma (ccRCC). Its proprietary OUTLAST™ platform metabolically reprograms T cells during manufacturing to thrive in the hostile tumor microenvironment, producing stem-like, exhaustion-resistant cells. The portfolio also includes CAR-M (macrophage) and CAR-NK (natural killer) cell therapy platforms in development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Superior preclinical efficacy demonstrated in aggressive RCC tumor model at low CAR-T doses and after tumor re-challenge
+2 more records
Product overview1 text field

Inceptor Bio is a clinical-stage biotechnology company developing a diversified portfolio of next-generation cell therapies for solid tumors. The company's core offering consists of the proprietary OUTLAST™ platform, which metabolically reprograms T cells to overcome the hostile tumor microenvironment. The lead product candidate IB-T101 is an autologous CAR-T therapy targeting CD70 for clear cell Renal Cell Carcinoma (ccRCC). The technology portfolio includes CAR-T, CAR-M (macrophage), and CAR-NK (natural killer) cell therapy platforms, all engineered to address the unique challenges of treating solid tumors that represent 90% of cancer cases.

Product and service3 records
1IB-T101
CategoryLead Product Candidate
Description

Autologous CAR-T cell therapy targeting CD70 for the treatment of clear cell Renal Cell Carcinoma (ccRCC), built on the OUTLAST™ platform to deliver stem-like, durable, exhaustion-resistant T cells for solid tumors.

2OUTLAST™ Platform
CategoryTechnology Platform
Description

Proprietary manufacturing platform that metabolically reprograms T cells by conditioning them in TME-like stress environments to produce stem-like, durable anti-tumor phenotypes with enhanced persistence, metabolic fitness, and resistance to exhaustion. All components are available at GMP grade.

3CAR-M Platform
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1GRIT Bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-18
Description

Strategic partnership to advance IB-T101, a potentially best-in-class CAR-T therapy targeting solid tumors. Inceptor grants GRIT Bio exclusive license for IB-T101 in China. GRIT Bio oversees development, manufacturing, and commercialization in China. Inceptor retains ex-China rights and is eligible for milestone payments and royalties upon IB-T101 achieving certain response criteria. Clinical data from this collaboration will support regulatory submissions and development in other regions.

inceptor.bio
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic CAR-T and CAR-NK therapies, including in oncology indications. Directly comparable as a next-generation cell therapy developer targeting hematologic and solid tumors with engineered immune cell platforms.

TypeDirect peer
Description

Pioneer in allogeneic CAR-T cell therapy with multiple clinical-stage oncology programs. Comparable as a well-capitalized cell therapy developer pursuing off-the-shelf alternatives to autologous approaches like Inceptor's IB-T101.

TypeDirect peer
Description

Clinical-stage biotech developing allogeneic and autologous CAR-NK cell therapies for cancer. Directly comparable through Inceptor's CAR-NK platform and shared focus on NK-based modalities for solid and hematologic tumors.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for cancer. Inceptor Bio advisor Chris Heery serves as Arcellx's CMO, illustrating direct operational and scientific overlap with Inceptor's CAR-T platform.

TypeDirect peer
Description

Clinical-stage gene-editing and cell therapy company developing allogeneic CAR-T therapies using its ARCUS platform. Highly comparable given shared scientific leadership (Mike Nicholson, Chris Heery previously held senior roles there) and CAR-T oncology focus.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered TCR-T therapies for solid tumors. Comparable as a solid-tumor-focused cell therapy developer pursuing durable responses through engineered T-cell receptors.

TypeDirect peer
Description

Clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell therapies for cancer. Comparable through its CAR-NK and engineered T-cell programs addressing solid tumors, with broader modality portfolio.

TypeDirect peer
Description

Clinical-stage cell therapy company developing CAR-T candidates including allogeneic and solid-tumor programs. Comparable as a CAR-T-focused oncology cell therapy developer advancing multiple clinical-stage programs.

TypeBroad incumbent
Description

Larger clinical- to commercial-stage gene and cell therapy company with approved Casgevy and a broad CAR-T pipeline. Comparable as a major cell therapy competitor and potential acquirer of next-generation platforms like OUTLAST™.

10Bristol Myers Squibb (Cell Therapy / ex-Juno)
TypeBroad incumbent
Description

Global oncology incumbent with multiple approved CAR-T products (Breyanzi, Abecma) inherited from the Juno Therapeutics acquisition. Multiple Inceptor board members and advisors previously led regulatory and process science at Juno/BMS, making it the most likely strategic acquirer or partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inceptor Bio

Cell Therapy / Oncology Biopharmaceuticalsinceptor.bio

Inceptor Bio is a clinical-stage biotech developing CAR-T, CAR-M, and CAR-NK cell therapies for solid tumors, with lead program IB-T101 targeting CD70 in clear cell renal cell carcinoma. Pre-revenue, it earns milestone and royalty revenue via territorial licensing partnerships.

What Inceptor Bio does

Inceptor Bio is a clinical-stage biotechnology company founded in May 2020 and headquartered in Morrisville, North Carolina (Research Triangle Park). The company develops engineered cell therapies — spanning CAR-T, CAR-M (macrophage), and CAR-NK (natural killer) modalities — for solid tumors. Its lead program, IB-T101, is an autologous CAR-T therapy directed at CD70-expressing cancers, with an initial indication in clear cell renal cell carcinoma (ccRCC); the first patient was dosed in February 2025 in a Phase 1 trial. The lead indication addresses a market of more than 300,000 new ccRCC cases annually worldwide.

The company's core technical differentiator is the OUTLAST™ platform, which metabolically reprograms T cells to persist and function within the hostile tumor microenvironment — a documented failure mode for conventional CAR-T therapies in solid tumors. Inceptor operates an in-house GMP manufacturing facility in Gainesville, Florida, acquired in 2022, providing process control and production independence for clinical supply. The pipeline also includes exploratory CAR-M and CAR-NK programs targeting the same CD70 antigen, and the company has established an in-house manufacturing footprint plus a series of preclinical data packages supporting the IB-T101 mechanism.

Inceptor is pre-revenue, with no approved or commercial products. Its business model is two-pronged: (1) internal development and eventual commercialization of proprietary cell therapies, either independently or with a future commercial partner, and (2) near-term licensing revenue through territorial partnerships — exemplified by its December 2024 deal with GRIT Bio granting China rights to IB-T101, which provides milestone and royalty upside. The company has raised approximately $84 million across multiple funding rounds since inception, with Kineticos Life Sciences as a consistent financial backer, and is led by CEO Matthias Schroff (formerly of Exicure) and Founder/Executive Chair Shailesh Maingi.

Inceptor Bio firmographics

Firmographics
Name
Inceptor Bio
Legal name
Inceptor Bio, LLC
Website
https://inceptor.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Inceptor Bio is a clinical-stage biotech developing CAR-T, CAR-M, and CAR-NK cell therapies for solid tumors, with lead program IB-T101 targeting CD70 in clear cell renal cell carcinoma. Pre-revenue, it earns milestone and royalty revenue via territorial licensing partnerships.
Ownership category
akta.pro rank

Inceptor Bio industry classification

Industry
Product category
Cell Therapy / Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy development
  • CAR-T therapy
  • Oncology biotechnology
  • Solid tumor treatment
  • Immunotherapy platform

Where Inceptor Bio is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Inceptor Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Therapy Development and Commercialization: Pre-revenue clinical stage biotechnology company developing cell therapies for cancer treatment. Revenue expected from future therapeutic product sales upon regulatory approval.
  2. Partnership Milestones and Royalties: Receives milestone payments and royalties from GRIT Bio partnership upon IB-T101 achieving certain response criteria and regulatory milestones in China.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Inceptor Bio product offering

Product offering

Core offering

Inceptor Bio develops next-generation autologous cell therapies for solid tumors, with lead candidate IB-T101, a CD70-targeted CAR-T therapy for clear cell Renal Cell Carcinoma (ccRCC). Its proprietary OUTLAST™ platform metabolically reprograms T cells during manufacturing to thrive in the hostile tumor microenvironment, producing stem-like, exhaustion-resistant cells. The portfolio also includes CAR-M (macrophage) and CAR-NK (natural killer) cell therapy platforms in development.

Product overview

Inceptor Bio is a clinical-stage biotechnology company developing a diversified portfolio of next-generation cell therapies for solid tumors. The company's core offering consists of the proprietary OUTLAST™ platform, which metabolically reprograms T cells to overcome the hostile tumor microenvironment. The lead product candidate IB-T101 is an autologous CAR-T therapy targeting CD70 for clear cell Renal Cell Carcinoma (ccRCC). The technology portfolio includes CAR-T, CAR-M (macrophage), and CAR-NK (natural killer) cell therapy platforms, all engineered to address the unique challenges of treating solid tumors that represent 90% of cancer cases.

Differentiator

Problem solved

Functional benefit

Brands

  • OUTLAST™ Platform: Proprietary platform that metabolically reprograms T cells to thrive in the hostile tumor microenvironment by conditioning for the fittest, most persistent cells through controlled TME-like stress.

Products and services

  • IB-T101 Autologous CAR-T cell therapy targeting CD70 for the treatment of clear cell Renal Cell Carcinoma (ccRCC), built on the OUTLAST™ platform to deliver stem-like, durable, exhaustion-resistant T cells for solid tumors.
  • OUTLAST™ Platform Proprietary manufacturing platform that metabolically reprograms T cells by conditioning them in TME-like stress environments to produce stem-like, durable anti-tumor phenotypes with enhanced persistence, metabolic fitness, and resistance to exhaustion. All components are available at GMP grade.
  • CAR-M Platform

Quantifiable outcome

  • Superior preclinical efficacy demonstrated in aggressive RCC tumor model at low CAR-T doses and after tumor re-challenge
  • +2 more outcomes

Companies that use Inceptor Bio

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Inceptor Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Inceptor Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GRIT BiocoreStrategic or Co-development Partner · 18 December 2024Strategic partnership to advance IB-T101, a potentially best-in-class CAR-T therapy targeting solid tumors. Inceptor grants GRIT Bio exclusive license for IB-T101 in China. GRIT Bio oversees development, manufacturing, and commercialization in China. Inceptor retains ex-China rights and is eligible for milestone payments and royalties upon IB-T101 achieving certain response criteria. Clinical data from this collaboration will support regulatory submissions and development in other regions.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Inceptor Bio competitors and assessment

Company assessment

Direct peers

  • Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T and CAR-NK therapies, including in oncology indications. Directly comparable as a next-generation cell therapy developer targeting hematologic and solid tumors with engineered immune cell platforms.
  • Allogene Therapeutics: Pioneer in allogeneic CAR-T cell therapy with multiple clinical-stage oncology programs. Comparable as a well-capitalized cell therapy developer pursuing off-the-shelf alternatives to autologous approaches like Inceptor's IB-T101.
  • Nkarta: Clinical-stage biotech developing allogeneic and autologous CAR-NK cell therapies for cancer. Directly comparable through Inceptor's CAR-NK platform and shared focus on NK-based modalities for solid and hematologic tumors.
  • Arcellx: Clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for cancer. Inceptor Bio advisor Chris Heery serves as Arcellx's CMO, illustrating direct operational and scientific overlap with Inceptor's CAR-T platform.
  • Precision BioSciences: Clinical-stage gene-editing and cell therapy company developing allogeneic CAR-T therapies using its ARCUS platform. Highly comparable given shared scientific leadership (Mike Nicholson, Chris Heery previously held senior roles there) and CAR-T oncology focus.
  • Adaptimmune: Clinical-stage cell therapy company developing engineered TCR-T therapies for solid tumors. Comparable as a solid-tumor-focused cell therapy developer pursuing durable responses through engineered T-cell receptors.
  • Fate Therapeutics: Clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell therapies for cancer. Comparable through its CAR-NK and engineered T-cell programs addressing solid tumors, with broader modality portfolio.
  • Poseida Therapeutics: Clinical-stage cell therapy company developing CAR-T candidates including allogeneic and solid-tumor programs. Comparable as a CAR-T-focused oncology cell therapy developer advancing multiple clinical-stage programs.

Broad incumbents

  • CRISPR Therapeutics: Larger clinical- to commercial-stage gene and cell therapy company with approved Casgevy and a broad CAR-T pipeline. Comparable as a major cell therapy competitor and potential acquirer of next-generation platforms like OUTLAST™.
  • Bristol Myers Squibb (Cell Therapy / ex-Juno): Global oncology incumbent with multiple approved CAR-T products (Breyanzi, Abecma) inherited from the Juno Therapeutics acquisition. Multiple Inceptor board members and advisors previously led regulatory and process science at Juno/BMS, making it the most likely strategic acquirer or partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Inceptor Bio social profiles

Digital presence

Inceptor Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inceptor Bio leadership team

Management profile

Number of profiles

Profiles11 records

Inceptor Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inceptor Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inceptor Bio

What does Inceptor Bio do?

Inceptor Bio develops next-generation autologous cell therapies for solid tumors, with lead candidate IB-T101, a CD70-targeted CAR-T therapy for clear cell Renal Cell Carcinoma (ccRCC). Its proprietary OUTLAST™ platform metabolically reprograms T cells during manufacturing to thrive in the hostile tumor microenvironment, producing stem-like, exhaustion-resistant cells. The portfolio also includes CAR-M (macrophage) and CAR-NK (natural killer) cell therapy platforms in development.

Is Inceptor Bio a public or private company?

Inceptor Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Inceptor Bio founded?

Inceptor Bio was founded in 2020. It employs 11 to 50 people.

Where is Inceptor Bio based?

Inceptor Bio is headquartered in Morrisville, United States, in the North America region.

How does Inceptor Bio make money?

Two revenue lines are on record. Therapy Development and Commercialization is the primary driver. The others are partnership Milestones and Royalties.

Who are Inceptor Bio's main competitors?

Direct peers on record are Caribou Biosciences, Allogene Therapeutics, Nkarta, Arcellx, Precision BioSciences, Adaptimmune, Fate Therapeutics and Poseida Therapeutics. Broad incumbents are CRISPR Therapeutics and Bristol Myers Squibb (Cell Therapy / ex-Juno).

Does Inceptor Bio have an API?

No public API is recorded for Inceptor Bio.

What industry is Inceptor Bio in?

Inceptor Bio's product category is Cell Therapy / Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InceptorInceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 FinancingInceptor Bio announced the first patient dosed in its IB-T101 clinical trial for clear cell renal cell carcinoma, a CD70-targeted CAR-T therapy. The company also closed a $21 million Series A2 financing led by Kineticos Life Sciences to support development. The trial will enroll patients across dose-escalation phases to determine optimal dosing.PR NewswireInceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 FinancingInceptor Bio announced the first patient dosed in its IB-T101 clinical trial for clear cell renal cell carcinoma, a CD70 CAR-T therapy. The company also closed a $21 million Series A2 financing led by Kineticos Life Sciences to support development.BioSpaceInceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 FinancingInceptor Bio announced the dosing of the first patient in a clinical trial of its lead therapy, IB-T101, for clear cell Renal Cell Carcinoma (ccRCC) and secured a $21 million Series A2 financing. The trial aims to evaluate safety, tolerability, and preliminary efficacy, and the funding will support further development.PR NewswireInceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ PlatformInceptor Bio and GRIT Bio announced a partnership to advance IB-T101, a CD70 CAR-T therapy for clear cell renal cell carcinoma. GRIT Bio will hold an exclusive license in China and oversee development, while Inceptor Bio may receive milestone payments and royalties. The collaboration aims to validate the OUTLAST platform for solid tumor treatments.SecSEC FORM DInceptor Bio, LLC filed a Form D with the SEC to report an exempt offering of securities under Rule 506(b). The company disclosed that it sold $15,875,000 USD worth of debt securities to 13 investors, with the first sale occurring on October 7, 2022. This filing serves as a regulatory notice regarding the completion of this specific capital raise.MedCity NewsWhile Auto vs. Allo Cell Therapy Debate Continues, VCs Look for ‘Next Shiny Thing’VCs and industry experts debate allogeneic cell therapy, citing durability concerns and clinical trial setbacks. They see in vivo cell editing as the next promising direction, while some companies like Inceptor Bio focus on autologous CAR-M therapies. Payment models may need to tie to therapy performance.PR NewswireInceptor Bio Appoints Matthias Schroff, PhD, as Chief Executive OfficerInceptor Bio, a North Carolina-based biotechnology company developing cell therapies for difficult-to-treat cancers, appointed Dr. Matthias Schroff as Chief Executive Officer effective May 8, 2023, succeeding Mr. Shailesh Maingi who remains as Executive Chairman. Dr. Schroff was most recently CEO of Exicure, a publicly traded biotech company, and previously held CEO positions at Vaximm AG and Mologen, bringing extensive experience in immuno-oncology, inflammatory diseases, and genetic disorders. The company described the appointment as occurring at an "important inflection point" as it advances its diversified pipeline of CAR-T, CAR-M, and CAR-NK cell therapies targeting solid tumors.BioSpaceSPONSORED: Closing the Opportunity Gap--How Inceptor Bio Supports Women LeadersInceptor Bio is closing the opportunity gap for women in life sciences through diversity, equity, and inclusion initiatives. The company, which launched in May 2022 with $37 million in Series A financing, has named conference rooms after influential women in science and supports local charities. Executives say these efforts build trust and confidence for women leaders.Labiotech.euOri Biotech and Inceptor Bio partner on solid tumor cell therapyOri Biotech and Inceptor Bio announced a partnership to use Ori's manufacturing platform for Inceptor's CAR-M, CAR-T, and CAR-NK programs. Inceptor is the third partner in Ori's LightSpeed Early Access Program, gaining pre-commercial access to the platform. The collaboration aims to accelerate process development ahead of clinical trials.SecSEC FORM DInceptor Bio, LLC filed a Notice of Exempt Offering of Securities with the Securities and Exchange Commission. The total offering amount is reported to be $13,875,000, with $2,625,000 already sold and $11,250,000 remaining to be sold. The offering is not associated with a business combination transaction.